Clinical Trial Results: Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing durvalumab and tremelimumab in recurrent or refractory ovarian, primary peritoneal, or fallopian tube cancer; results completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2026-08-05